When can the patient with deep venous thrombosis begin to ambulate?
Aldrich
Dana
D
The Institute for Rehabilitation and Research, 1333 Moursund, Houston, TX 77030, USA. aldrid@tirr.tmc.edu
Hunt
Daniel P
DP
D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D001458:Bandages; D001510:Bed Rest; D016022:Case-Control Studies; D015331:Cohort Studies; D004434:Early Ambulation; D005081:Exercise Therapy; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007103:Immobilization; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D011655:Pulmonary Embolism / Q000175:diagnosis / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors; D012449:Safety; D013923:Thromboembolism / Q000517:prevention & control; D013924:Thrombophlebitis / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control / Q000534:rehabilitation*; D013997:Time Factors; D020246:Venous Thrombosis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000534:rehabilitation*; D016138:Walking
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin